# The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

> **NCT04452929** · NA · UNKNOWN · sponsor: **Danish Headache Center** · enrollment: 72 (estimated)

## Conditions studied

- Migraine
- Migraine Without Aura
- Migraine With Aura

## Interventions

- **DRUG:** Erenumab
- **DRUG:** Placebo
- **DRUG:** Calcitonin gene-related peptide
- **DRUG:** Cilostazol

## Key facts

- **NCT ID:** NCT04452929
- **Lead sponsor:** Danish Headache Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-22
- **Primary completion:** 2022-02
- **Final completion:** 2022-07
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2020-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04452929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04452929, "The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04452929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*